Looking to the future in chronic lymphocytic leukemia (CLL) treatment, John Seymour, MBBS, PhD, of the Peter MacCallum Cancer Center, Victoria, Australia, discusses his thoughts on the most promising directions for deep responses that are both economical and well tolerated, including the combination of BTK and BCL-2 inhibitors. This video was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.